We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

28 hedge funds and large institutions have $42.8M invested in Xilio Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.18% less ownership

Funds ownership: 4.32% → 4.14% (-0.18%)

3% less funds holding

Funds holding: 29 → 28 (-1)

11% less capital invested

Capital invested by funds: $48.3M → $42.8M (-$5.49M)

Holders
28
Holders Change
-1
Holders Change %
-3.45%
% of All Funds
0.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
7
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Bank of America
Bank of America
North Carolina
+$562K
2
BCM
Bridgeway Capital Management
Texas
+$82.9K
3
Morgan Stanley
Morgan Stanley
New York
+$45.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$20.7K
5
BlackRock
BlackRock
New York
+$7.42K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$752K
2
SCM
Soleus Capital Management
Connecticut
-$546K
3
E
Ergoteles
New York
-$38K
4
RC
RBF Capital
California
-$29K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$2.83K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$7.55M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$7.42M – – –
OCA
3
Octagon Capital Advisors
New York
$6.52M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$5.13M -$752K -22,292 -14%
RVM
5
RiverVest Venture Management
Missouri
$3.88M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$3.67M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.4M -$2.83K -84 -0.1%
AG
8
Artal Group
Luxembourg
$1.21M – – –
HMC
9
Harvard Management Company
Massachusetts
$1.12M – – –
TOCUITCONY
10
Trustees of Columbia University in the City of New York
New York
$672K +$602K +17,831 New
Bank of America
11
Bank of America
North Carolina
$627K +$562K +16,648 New
SCM
12
Soleus Capital Management
Connecticut
$610K -$546K -16,194 -50%
Fidelity International
13
Fidelity International
Bermuda
$588K – – –
LCM
14
Laurion Capital Management
New York
$384K – – –
BCM
15
Bridgeway Capital Management
Texas
$297K +$82.9K +2,458 +45%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$227K +$2.73K +81 +1%
BlackRock
17
BlackRock
New York
$133K +$7.42K +220 +7%
Renaissance Technologies
18
Renaissance Technologies
New York
$100K +$20.7K +614 +30%
Millennium Management
19
Millennium Management
New York
$72K -$1.79K -53 -3%
Morgan Stanley
20
Morgan Stanley
New York
$68.9K +$45.2K +1,340 +274%
CC
21
Cannell Capital
Wyoming
$45.8K – – –
State Street
22
State Street
Massachusetts
$42.2K – – –
Northern Trust
23
Northern Trust
Illinois
$34.7K – – –
NL
24
NWAM LLC
Washington
$26.9K – – –
TRCT
25
Tower Research Capital (TRC)
New York
$11K +$5.26K +156 +105%
1
2

XLO Hedge Fund Activity: Q4 2022 in Review

28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2022, worth a combined $42.8M — down 11% from $48.3M a quarter earlier.

Fund positioning in XLO was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Bank of America, opening a new position worth an estimated $562K. The largest seller was Fidelity Investments, cutting an estimated $752K.

  • 28 institutional investors held Xilio Therapeutics (XLO) as of Q4 2022, down from 29 in Q3 2022.
  • Funds reported $42.8M of Xilio Therapeutics stock for Q4 2022, down 11% quarter-over-quarter.
  • 2 funds opened new Xilio Therapeutics positions in Q4 2022 and 2 closed out, a net change of 0 holders.
  • The largest Xilio Therapeutics buyer in Q4 2022 was Bank of America, an estimated $562K added.
  • The largest Xilio Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $752K sold.

Based on aggregated 13F filings for Q4 2022.